Unlock stock picks and a broker-level newsfeed that powers Wall Street.

LSE - Delayed Quote GBp

Genflow Biosciences plc (GENF.L)

0.8750
-0.1500
(-14.63%)
At close: May 2 at 4:28:53 PM GMT+1
Loading Chart for GENF.L
  • Previous Close 1.0250
  • Open 0.9733
  • Bid 0.8500 x --
  • Ask 0.9000 x --
  • Day's Range 0.8500 - 1.0000
  • 52 Week Range 0.8500 - 3.4060
  • Volume 6,265,558
  • Avg. Volume 2,094,583
  • Market Cap (intraday) 4.008M
  • Beta (5Y Monthly) 2.39
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date May 1, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use. Genflow Biosciences plc was incorporated in 2021 and is headquartered in London, the United Kingdom.

genflowbio.com

5

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GENF.L

View More

Performance Overview: GENF.L

Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

GENF.L
49.28%
FTSE 100 (^FTSE)
5.18%

1-Year Return

GENF.L
57.32%
FTSE 100 (^FTSE)
5.19%

3-Year Return

GENF.L
90.28%
FTSE 100 (^FTSE)
13.94%

5-Year Return

GENF.L
90.54%
FTSE 100 (^FTSE)
49.16%

Compare To: GENF.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GENF.L

View More

Valuation Measures

Annual
As of 4/30/2025
  • Market Cap

    3.42M

  • Enterprise Value

    3.14M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    4.67

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -256.07%

  • Return on Assets (ttm)

    -58.66%

  • Return on Equity (ttm)

    -118.88%

  • Revenue (ttm)

    598.04k

  • Net Income Avi to Common (ttm)

    -1.53M

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.14M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -461.18k

Research Analysis: GENF.L

View More

Company Insights: GENF.L

Research Reports: GENF.L

View More

People Also Watch